+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Screening for EGFR mutations in lung cancer



Screening for EGFR mutations in lung cancer



Discovery Medicine 8(43): 181-184



Certain mutations in the epidermal growth factor receptor (EGFR) gene confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small cell lung cancer. Large-scale screening for EGFR mutations in such patients is feasible for predicting response to TKIs and thus guiding treatment.

(PDF emailed within 1 workday: $29.90)

Accession: 055670747

Download citation: RISBibTeXText

PMID: 20040267


Related references

Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? No, EGFR TKIs should be reserved for patients with EGFR mutations. Clinical Advances in Hematology & Oncology 14(1): 41, 44-5, 2016

Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer 73(3): 316-319, 2011

Screening for germline EGFR T790M mutations through lung cancer genotyping. Journal of Thoracic Oncology 7(6): 1049-1052, 2012

Should EGFR tyrosine kinase inhibitors be used in non-small cell lung cancer in the absence of EGFR mutations? Yes, there is a role for EGFR TKIs in these patients. Clinical Advances in Hematology & Oncology 14(1): 41-43, 2016

Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer. European Respiratory Journal 38(4): 903-910, 2012

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors. Lung Cancer 73(1): 96-102, 2011

Frequency of EGFR mutations in non-small cell lung cancer patients: screening data from West Siberia. Asian Pacific Journal of Cancer Prevention 16(2): 689-692, 2015

Screening for EGFR mutations in lung cancer by a novel real-time PCR with double-loop probe and Sanger DNA sequencing. Zhonghua Zhong Liu Za Zhi 35(1): 28-32, 2013

PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. Plos One 9(2): E88291-E88291, 2015

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. Journal of the National Comprehensive Cancer Network 12(1): 6-11; Quiz 11, 2014

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. Journal of Clinical Oncology 33(17): 1958-1965, 2015

Screening for EGFR and KRAS mutations in endobronchial ultrasound derived transbronchial needle aspirates in non-small cell lung cancer using COLD-PCR. Plos One 6(9): E25191-E25191, 2012

Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harbor Symposia on Quantitative Biology 70: 419-426, 2006

EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer. Seminars in Oncology Nursing 24(1): 27-33, 2008

The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study. Bmj Open 3(4): -, 2013